Dashe Jodi S, Sheffield Jeanne S, Olscher Debora A, Todd Sally J, Jackson Gregory L, Wendel George D
Department of Obstetrics & Gynecology, The University of Texas Southwestern Medical Center, Dallas, USA.
Obstet Gynecol. 2002 Dec;100(6):1244-9. doi: 10.1016/s0029-7844(02)02387-6.
To determine whether maternal methadone dosage affects duration and degree of neonatal narcotic withdrawal.
This was a retrospective cohort study of pregnant women with opioid addiction who delivered live-born singletons between April 1990 and April 2001. Inpatient detoxification or outpatient methadone maintenance therapy was offered. Women who had a positive drug screen or whose neonate tested positive for opioids were considered to be supplementing. We evaluated indices of neonatal withdrawal according to the maximum daily methadone dosage in the last week of pregnancy.
Seventy women with opioid addiction were followed. Median methadone dosage was 20 mg (range 0-150 mg), and 32 infants (46%) were treated for narcotic withdrawal. Among women who received less than 20 mg per day, 20-39 mg per day, and at least 40 mg per day of methadone, treatment for withdrawal occurred in 12%, 44%, and 90% of infants, respectively (P < 0.02). Methadone dosage was also correlated with both duration of neonatal hospitalization and neonatal abstinence score (r(s) =.70 and.73 respectively, both P <.001). Neonates were more likely to experience withdrawal if their mothers were supplementing with heroin, 68% versus 35% (P =.01). Regardless of supplementation, there was a significant relationship between methadone dosage and neonatal withdrawal (P <.05).
Maternal methadone dosage was associated with duration of neonatal hospitalization, neonatal abstinence score, and treatment for withdrawal. Heroin supplementation did not alter this dose-response relationship. In selected pregnancies, lowering the maternal methadone dosage was associated with both decreased incidence and severity of neonatal withdrawal.
确定母亲美沙酮剂量是否会影响新生儿戒断症状的持续时间和严重程度。
这是一项对1990年4月至2001年4月间分娩单胎活产儿的阿片类药物成瘾孕妇进行的回顾性队列研究。提供住院戒毒或门诊美沙酮维持治疗。药物筛查呈阳性或其新生儿阿片类药物检测呈阳性的妇女被视为正在补充药物。我们根据妊娠最后一周的美沙酮最大日剂量评估新生儿戒断指标。
对70名阿片类药物成瘾妇女进行了随访。美沙酮剂量中位数为20毫克(范围0 - 150毫克),32名婴儿(46%)接受了戒断治疗。在每天接受美沙酮剂量低于20毫克、20 - 39毫克和至少40毫克的妇女中,分别有12%、44%和90%的婴儿接受了戒断治疗(P < 0.02)。美沙酮剂量还与新生儿住院时间和新生儿戒断评分相关(斯皮尔曼相关系数分别为0.70和0.73,均P < 0.001)。如果母亲正在补充海洛因,新生儿更有可能出现戒断症状,比例分别为68%和35%(P = 0.01)。无论是否补充药物,美沙酮剂量与新生儿戒断之间均存在显著关系(P < 0.05)。
母亲美沙酮剂量与新生儿住院时间、新生儿戒断评分及戒断治疗有关。补充海洛因并未改变这种剂量反应关系。在特定妊娠中,降低母亲美沙酮剂量与新生儿戒断发生率和严重程度的降低均有关。